Brokers Set Expectations for Innoviva FY2025 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Innoviva in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the biotechnology company will post earnings of $1.55 per share for the year. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share.

Separately, StockNews.com cut shares of Innoviva from a “buy” rating to a “hold” rating in a report on Tuesday, December 31st.

Innoviva Trading Down 1.2 %

Innoviva stock opened at $18.53 on Wednesday. The company’s fifty day simple moving average is $18.34 and its 200-day simple moving average is $18.77. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. Innoviva has a 12 month low of $14.32 and a 12 month high of $21.28. The stock has a market cap of $1.16 billion, a P/E ratio of 26.86 and a beta of 0.54.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The company had revenue of $89.51 million for the quarter.

Institutional Investors Weigh In On Innoviva

Several institutional investors and hedge funds have recently modified their holdings of INVA. American Century Companies Inc. lifted its stake in shares of Innoviva by 369.6% in the 2nd quarter. American Century Companies Inc. now owns 459,690 shares of the biotechnology company’s stock valued at $7,539,000 after purchasing an additional 361,797 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Innoviva by 1.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,684,594 shares of the biotechnology company’s stock valued at $76,826,000 after purchasing an additional 71,336 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Innoviva by 25.3% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 29,420 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 5,940 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of Innoviva by 45.3% in the 2nd quarter. Hsbc Holdings PLC now owns 57,832 shares of the biotechnology company’s stock valued at $936,000 after purchasing an additional 18,026 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Innoviva in the 2nd quarter valued at $249,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.